Establishment of a prognosis-related predictive model for hepatocellular carcinoma patients with macrovascular invasion treated with transcatheter arterial chemoembolization combined with intensity modulated radiotherapy.
Dan Yang, Wanting Tian, Wei Wang, Xuan Zhao, Chaozhi Wang, Zhufang Ma
{"title":"Establishment of a prognosis-related predictive model for hepatocellular carcinoma patients with macrovascular invasion treated with transcatheter arterial chemoembolization combined with intensity modulated radiotherapy.","authors":"Dan Yang, Wanting Tian, Wei Wang, Xuan Zhao, Chaozhi Wang, Zhufang Ma","doi":"10.21037/tcr-24-1226","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>So far, there are still few studies on the prognostic factors of hepatocellular carcinoma (HCC) patients with macrovascular invasion (MVI) treated with transcatheter arterial chemoembolization (TACE) combined with intensity modulated radiotherapy (IMRT), and no relevant model has been established to predict the prognosis of such patients. Thus, the purpose of this study was to determine the prognostic factors of HCC patients with MVI after treatment with TACE combined with IMRT, and to establish a nomogram model for forecasting 1-, 3-, 5-year overall survival (OS) of the patients.</p><p><strong>Methods: </strong>HCC patients with MVI who were diagnosed and treated at Department of Gastroenterology, 3201 Hospital between January 2010 and December 2020 were enrolled in this study according to the inclusion and exclusion criteria. The risk factors linked to patient OS were determined by performing Cox regression analysis. The nomogram for predicting 1-, 3-, 5-year OS in HCC patients with MVI was stablished and validated based on the results of the Cox regression analysis.</p><p><strong>Results: </strong>In total, 118 patients were included in the current study. The medium follow-up time was 46 months (range, 29-71 months). Univariate Cox regression analysis revealed that tumor diameter, treatment frequency of TACE, IMRT dose, Child-Pugh grade, liver cirrhosis and alpha fetoprotein (AFP) level were significantly related to the OS of the patients. Further multivariate Cox regression analysis showed that treatment frequency of TACE and Child-Pugh grade, liver cirrhosis and AFP level were the independent prognostic factors of the OS in patients who were treated with TACE combined with IMRT. The nomogram we constructed using the above independent risk factors exhibited good ability for predicting 1-, 3-, 5-year OS of the patients. The concordance-index of the nomogram was 0.727, indicating the nomogram had a good discrimination.</p><p><strong>Conclusions: </strong>Treatment frequency of TACE and Child-Pugh grade, liver cirrhosis and AFP level were independent predictors of OS in HCC patients with MVI after TACE combined with IMRT treatment. The nomogram that we developed using these predictors provided a convenient tool to predict the survival probability in HCC patients with MVI.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"1214-1222"},"PeriodicalIF":1.5000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912082/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-1226","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/24 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: So far, there are still few studies on the prognostic factors of hepatocellular carcinoma (HCC) patients with macrovascular invasion (MVI) treated with transcatheter arterial chemoembolization (TACE) combined with intensity modulated radiotherapy (IMRT), and no relevant model has been established to predict the prognosis of such patients. Thus, the purpose of this study was to determine the prognostic factors of HCC patients with MVI after treatment with TACE combined with IMRT, and to establish a nomogram model for forecasting 1-, 3-, 5-year overall survival (OS) of the patients.
Methods: HCC patients with MVI who were diagnosed and treated at Department of Gastroenterology, 3201 Hospital between January 2010 and December 2020 were enrolled in this study according to the inclusion and exclusion criteria. The risk factors linked to patient OS were determined by performing Cox regression analysis. The nomogram for predicting 1-, 3-, 5-year OS in HCC patients with MVI was stablished and validated based on the results of the Cox regression analysis.
Results: In total, 118 patients were included in the current study. The medium follow-up time was 46 months (range, 29-71 months). Univariate Cox regression analysis revealed that tumor diameter, treatment frequency of TACE, IMRT dose, Child-Pugh grade, liver cirrhosis and alpha fetoprotein (AFP) level were significantly related to the OS of the patients. Further multivariate Cox regression analysis showed that treatment frequency of TACE and Child-Pugh grade, liver cirrhosis and AFP level were the independent prognostic factors of the OS in patients who were treated with TACE combined with IMRT. The nomogram we constructed using the above independent risk factors exhibited good ability for predicting 1-, 3-, 5-year OS of the patients. The concordance-index of the nomogram was 0.727, indicating the nomogram had a good discrimination.
Conclusions: Treatment frequency of TACE and Child-Pugh grade, liver cirrhosis and AFP level were independent predictors of OS in HCC patients with MVI after TACE combined with IMRT treatment. The nomogram that we developed using these predictors provided a convenient tool to predict the survival probability in HCC patients with MVI.
期刊介绍:
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.